279. 巨大静脈奇形(頚部口腔咽頭びまん性病変) [臨床試験数:7,薬物数:16(DrugBank:6),標的遺伝子数:1,標的パスウェイ数:43]
Searched query = "Huge venous malformation with cervical, oral and pharyngeal diffuse lesion", "Huge venous malformation", "Venous malformation"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03767660 | July 31, 2018 | 18 December 2018 | Efficacy of Rapamycin (Sirolimus) in the Treatment of BRBNS, Hereditary or Sporadic Venous Malformation | Efficacy of Rapamycin (Sirolimus) in the Treatment of Blue Rubber Bleb Nevus Syndrome, Hereditary or Sporadic Venous Malformation | Blue Rubber Bleb Nevus Syndrome;Venous Malformation | Drug: Rapamycin | Peking Union Medical College Hospital | Air Force General Hospital of the PLA;Chinese Academy of Medical Sciences | Recruiting | N/A | N/A | All | 20 | Phase 4 | China |
2 | ChiCTR-OIB-15007455 | 2015-03-18 | 18 April 2017 | Effect of sclerotherapy on venous malformation associated with localized intravascular coagulopathy: A prospective, before-after controlled study | Effect of sclerotherapy on venous malformation associated with localized intravascular coagulopathy: A prospective, before-after controlled study | venous malformation | 1:sclerotherapy with ethanol; | Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | Both | 1:40; | Phase 1 study | China | |||
3 | NCT01347294 | August 2011 | 16 December 2017 | Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations | Compare the Effect of Bleomycin and Tetradecyl Sodium Sulphate in the Treatment of Venous Malformations | Venous Malformation | Drug: Bleomycin;Drug: Fibrovein;Drug: Bleomycin + Fibrovein | Oslo University Hospital | Recruiting | 12 Years | 80 Years | All | 126 | Phase 4 | Norway | |
4 | JPRN-jRCTs071180067 | 23/10/2009 | 10 September 2019 | Clinical research of intralesional sclerotherapy in the oral and maxillofacial region | Clinical research for safty and efficacy in intralesional sclerotherapy with ethanolamine oleate for subcutaneous venous malformation in the oral and maxillofacial region - EOST-OMS | Venous malformation in the oral and maxillofacial region Sclerotherapy, Venous malformation, ethanolamine oleate;angioma, venous | Single arm study, open (masking not used), no assignment All procedures will be done with oral surgeon and radiologist in angiography room. (For superficial lesion, procedures will be done with intermittent simple X-ray for reduction of exposure, despite using angiography to confirm drainage veins in oral and maxillofacial outpatient clinic.) 1. Local anesthesia into the lesion. 2. Puncture with 22-24G needle and confirm the backflow of blood. 3. Stabilize the needle and check the distribution and blood flow of the lesion by angiography and computed tomography (CT) with contrast medium. If there is any risk that sclerosing agent will escape whole body, we must decide the cancellation of the trial. If we can block the drainage vein over 5 minutes, we decide that the trial can continue. (For superficial lesions, we inject contrast medium in oral and maxillofacial outpatient clinic and confirm retention of contrast medium using intermittent simple X-ray.) 4. Treat with injection 5% ethanolamine oleate(EO) (diluted by Iopamiron 300) . Volume of the 5%EO will be decided by situation, but the maximum volume is 20ml (5% EO) by one treatment. After 5 minites, the 5%EO collect as possible. 5. Check the hemostasis of the injection point(s). | Atsushi Danjo | Recruiting | Not applicable | Not applicable | Both | 25 | Phase 2 | none | |
5 | NCT00975819 | October 2009 | 19 February 2015 | Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies | A Phase 2 Study - Clinical Trial Assessing Efficacy and Safety of the mTOR Inhibitor Sirolimus in the Treatment of Complicated Vascular Anomalies | Kaposiform Hemangioendotheliomas;Tufted Angioma;Capillary Venous Lymphatic Malformation;Venous Lymphatic Malformation;Microcystic Lymphatic Malformation;Mucocutaneous Lymphangiomatosis and Thrombocytopenia;Capillary Lymphatic Arterial Venous Malformations;PTEN Overgrowth Syndrome With Vascular Anomaly;Lymphangiectasia Syndromes | Drug: sirolimus | Children's Hospital Medical Center, Cincinnati | Not recruiting | N/A | 31 Years | Both | 60 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | EUCTR2009-011276-29-FR | 21/08/2009 | 19 March 2012 | Systemic and local diffusion of ethanol after administration of ethanol 96% formulated in a gel (L0122 Gel) and ethanol 98% solution (absolute ethanol) by the percutaneous route, in patients with congenital venous malformations (CVM): pharmacokinetic, pharmacodynamic and clinical study. | Systemic and local diffusion of ethanol after administration of ethanol 96% formulated in a gel (L0122 Gel) and ethanol 98% solution (absolute ethanol) by the percutaneous route, in patients with congenital venous malformations (CVM): pharmacokinetic, pharmacodynamic and clinical study. | patients with congenital venous malformations (CVM) | Product Name: Ethanol gel Product Code: L0122 Pharmaceutical Form: Gel for injection CAS Number: 64-17-5 Other descriptive name: ETHANOL (96 PER CENT) Concentration unit: % (W/W) percent weight/weight Concentration type: equal Concentration number: 94.12- Trade Name: Dehydrated Alcohol (Absolute Alcohol) BP for Injection Product Name: Dehydrated Alcohol (Absolute Alcohol) BP for Injection Pharmaceutical Form: Solution for injection CAS Number: 64-17-5 Other descriptive name: ETHANOL BP Concentration unit: % (V/V) percent volume/volume Concentration type: equal Concentration number: 100- | ORFAGEN | Authorised | Female: yes Male: yes | 24 | France | ||||
7 | NCT00462462 | May 2007 | 19 October 2017 | Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study. | Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study. | Congenital Venous Malformation | Drug: Ethanol 96% Gel;Drug: Ethanol 98% Solution | Orfagen | FDA Office of Orphan Products Development | Not recruiting | 12 Years | N/A | All | 32 | Phase 2 | United States;France |